Randomized, Double-Masked, Sham-Controlled Trial of
... receiving PDT in the study eye could continue study treatment, but PDT could not be given less than 28 days before or less than 21 days after a study injection. Also, PDT in the nonstudy eye could not be given less than five days before or less than 21 days after a study injection. No independent ch ...
... receiving PDT in the study eye could continue study treatment, but PDT could not be given less than 28 days before or less than 21 days after a study injection. Also, PDT in the nonstudy eye could not be given less than five days before or less than 21 days after a study injection. No independent ch ...
Optimal asthma control, starting with high doses of inhaled budesonide
... polated values were calculated when the FEV1 fell by >20% with the first histamine dose, or when the FEV1 fell by <20% at the final dose of 7.8 mmol (maximum extrapolated value 15.6 mmol). A PD20 of $3.92 mmol (approximately equivalent to a provocative concentration of histamine causing a 20% fall i ...
... polated values were calculated when the FEV1 fell by >20% with the first histamine dose, or when the FEV1 fell by <20% at the final dose of 7.8 mmol (maximum extrapolated value 15.6 mmol). A PD20 of $3.92 mmol (approximately equivalent to a provocative concentration of histamine causing a 20% fall i ...
Scientific Report 2012-2013 - Institut National Du Cancer
... support from the two supervising ministries, the International Scientific Advisory Board and Board of Directors, INCa will have provided continuous financial support for research projects (and maintained and increased this support during budget restrictions) by relying on transparent methods, intern ...
... support from the two supervising ministries, the International Scientific Advisory Board and Board of Directors, INCa will have provided continuous financial support for research projects (and maintained and increased this support during budget restrictions) by relying on transparent methods, intern ...
Study Protocol Phase II clinical trial testing the safety and efficacy of
... Testimony was submitted by Dr. Greer (who had administered MDMA to about 80 individuals and reported apparent benefits to the therapeutic alliance and to outcomes), Dr. Downing (who reported use of MDMA with 8 patients, 5 of whom he considered to have shown accelerated therapeutic progress), and Dr. ...
... Testimony was submitted by Dr. Greer (who had administered MDMA to about 80 individuals and reported apparent benefits to the therapeutic alliance and to outcomes), Dr. Downing (who reported use of MDMA with 8 patients, 5 of whom he considered to have shown accelerated therapeutic progress), and Dr. ...
Final Program - Society for Clinical Trials
... and medical device companies, biotechs, and CROs, accelerates study startup, providing a simpler, more intuitive way to efficiently manage studies. NIH Office of Biotechnology Activities – Booth 7 The NIH has established the Clinical Research Policy Analysis and Coordination (CRpac) Program to serve ...
... and medical device companies, biotechs, and CROs, accelerates study startup, providing a simpler, more intuitive way to efficiently manage studies. NIH Office of Biotechnology Activities – Booth 7 The NIH has established the Clinical Research Policy Analysis and Coordination (CRpac) Program to serve ...
Stroke - Multidisciplinary Association for Psychedelic Studies
... study of the therapeutic use of MDMA in any patient population has yet to be conducted, despite considerable efforts to obtain permission for such studies. Samuel Widmer, MD, Peter Gasser, MD, and other members of the Swiss Medical Society for Psycholytic Therapy received permission from the Swiss M ...
... study of the therapeutic use of MDMA in any patient population has yet to be conducted, despite considerable efforts to obtain permission for such studies. Samuel Widmer, MD, Peter Gasser, MD, and other members of the Swiss Medical Society for Psycholytic Therapy received permission from the Swiss M ...
Phase II clinical trial testing the safety and efficacy
... Testimony was submitted by Dr. Greer (who had administered MDMA to about 80 individuals and reported apparent benefits to the therapeutic alliance and to outcomes), Dr. Downing (who reported use of MDMA with 8 patients, 5 of whom he considered to have shown accelerated therapeutic progress), and Dr. ...
... Testimony was submitted by Dr. Greer (who had administered MDMA to about 80 individuals and reported apparent benefits to the therapeutic alliance and to outcomes), Dr. Downing (who reported use of MDMA with 8 patients, 5 of whom he considered to have shown accelerated therapeutic progress), and Dr. ...
Laboratory based effects of infrasound protocol Master
... The main community group advocating that wind farms have deleterious effects on health is the Waubra Foundation. The foundation’s chair, Mr Peter Mitchell recently served as an observer on the NHMRC Wind Farms Health Effects Reference Group. The foundation recently published a statement “Acoustic ...
... The main community group advocating that wind farms have deleterious effects on health is the Waubra Foundation. The foundation’s chair, Mr Peter Mitchell recently served as an observer on the NHMRC Wind Farms Health Effects Reference Group. The foundation recently published a statement “Acoustic ...
CHMP assessment report Note Zydelig
... small lymphocytic lymphoma (SLL) as the same biological entity, with CLL clinically manifesting primarily in bone marrow and peripheral blood, and SLL primarily manifesting in the lymph nodes. Current treatments for CLL are not curative. Fewer patients obtain responses with each subsequent regimen, ...
... small lymphocytic lymphoma (SLL) as the same biological entity, with CLL clinically manifesting primarily in bone marrow and peripheral blood, and SLL primarily manifesting in the lymph nodes. Current treatments for CLL are not curative. Fewer patients obtain responses with each subsequent regimen, ...
Extract from the Clinical Evaluation Report for Rituximab
... In the event that the patient experienced an infusion-related reaction, the infusion rate was to be reduced to half that rate (for example, from 100 mg/hour to 50 mg/hour). Once the AE had resolved, the investigator was to wait an additional 30 minutes while delivering the infusion at the reduced ra ...
... In the event that the patient experienced an infusion-related reaction, the infusion rate was to be reduced to half that rate (for example, from 100 mg/hour to 50 mg/hour). Once the AE had resolved, the investigator was to wait an additional 30 minutes while delivering the infusion at the reduced ra ...
Protocol S1.
... ‡ The external genital wart/lesion exam must be conducted in 2 parts in order to limit contamination between anatomical areas. The external portion of the exam including vulvar, labia, perineum, perianal and other external areas will be performed prior to the pelvic exam. The vaginal portion of the ...
... ‡ The external genital wart/lesion exam must be conducted in 2 parts in order to limit contamination between anatomical areas. The external portion of the exam including vulvar, labia, perineum, perianal and other external areas will be performed prior to the pelvic exam. The vaginal portion of the ...
friday, september 30, 2016
... together an outstanding faculty of Canadian and international speakers who will share their expertise and insights as they cover the wide spectrum of clinical and basic sciences. As the primary Canadian gathering for the allergy community, it will provide an excellent opportunity for specialists and ...
... together an outstanding faculty of Canadian and international speakers who will share their expertise and insights as they cover the wide spectrum of clinical and basic sciences. As the primary Canadian gathering for the allergy community, it will provide an excellent opportunity for specialists and ...
Publicly funded Practice-oriented Clinical Trials
... Figure 13 – Clinical trials with CTA, situation of Belgium within Europe.14, 120 ...................................................47 Figure 14 – Drivers for a pharmaceutical company to choose Belgium as clinical trial location, compared with global drivers for location choice.14, 120 ............. ...
... Figure 13 – Clinical trials with CTA, situation of Belgium within Europe.14, 120 ...................................................47 Figure 14 – Drivers for a pharmaceutical company to choose Belgium as clinical trial location, compared with global drivers for location choice.14, 120 ............. ...
IIH:WT Trial Protocol - University of Birmingham
... The Chief Investigator and the Sponsor have discussed this protocol. The Investigator agrees to perform the investigations and to abide by this protocol. The Investigator agrees to conduct the trial in compliance with the approved protocol, EU Good Clinical Practice (GCP), the UK Clinical Trials Reg ...
... The Chief Investigator and the Sponsor have discussed this protocol. The Investigator agrees to perform the investigations and to abide by this protocol. The Investigator agrees to conduct the trial in compliance with the approved protocol, EU Good Clinical Practice (GCP), the UK Clinical Trials Reg ...
Information on Clinical Investigation Plan (CIP) Template
... plan; the known side effects and any risks involved in taking part. It will be clearly stated that the participant is free to withdraw from the clinical investigation at any ...
... plan; the known side effects and any risks involved in taking part. It will be clearly stated that the participant is free to withdraw from the clinical investigation at any ...
FDG-PET/CT - QIBA Wiki
... Clearly identify purposes for which such imaging may be used: eligibility determination, sample enrichment, stratification, setting the measurement base-line, etc. (e.g. What characteristics or timing will make the imaging acceptable for the purpose? Will digitized films be accepted? Will low-grade ...
... Clearly identify purposes for which such imaging may be used: eligibility determination, sample enrichment, stratification, setting the measurement base-line, etc. (e.g. What characteristics or timing will make the imaging acceptable for the purpose? Will digitized films be accepted? Will low-grade ...
2010 Annual Research Report, Princess Alexandra Hospital
... this publication may be reproduced by any process without prior written permission from the Princess Alexandra Hospital Centres for Health Research. Enquiries should be directed to the Director, Research Development & Ethics, Centres for Health Research, Princess Alexandra Hospital. ...
... this publication may be reproduced by any process without prior written permission from the Princess Alexandra Hospital Centres for Health Research. Enquiries should be directed to the Director, Research Development & Ethics, Centres for Health Research, Princess Alexandra Hospital. ...
Transparency and Registration in Clinical Research in the Nordic
... taken of all the means reasonably likely to be used either by the controller or by any other person to identify or single out the individual directly or indirectly. To ascertain whether means are reasonably likely to be used to identify the individual, account should be taken of all objective factor ...
... taken of all the means reasonably likely to be used either by the controller or by any other person to identify or single out the individual directly or indirectly. To ascertain whether means are reasonably likely to be used to identify the individual, account should be taken of all objective factor ...
Clinical features and determinants of COPD exacerbation in the Hokkaido COPD
... health-related QoL) compared to subjects who had no exacerbation (table S2). Among subjects who experienced at least one exacerbation, 50% of subjects by symptom definition, 48% by prescription definition, 42% by antibiotics definition and 25% by admission definition developed multiple exacerbation ...
... health-related QoL) compared to subjects who had no exacerbation (table S2). Among subjects who experienced at least one exacerbation, 50% of subjects by symptom definition, 48% by prescription definition, 42% by antibiotics definition and 25% by admission definition developed multiple exacerbation ...
Protocol S1.
... Send an e-mail message to [email protected] (ATTN: Evelyn Hogg). Copies of the Protocol To request copies of the protocol: Hard copies: Send an e-mail message to [email protected] (ATTN: Diane Delgado). Electronic copies can be downloaded from the Members area of the ACTG Web site (ht ...
... Send an e-mail message to [email protected] (ATTN: Evelyn Hogg). Copies of the Protocol To request copies of the protocol: Hard copies: Send an e-mail message to [email protected] (ATTN: Diane Delgado). Electronic copies can be downloaded from the Members area of the ACTG Web site (ht ...
CTIMP Protocol development tool
... Aim: To outline the various committees or groups involved in trial coordination and conduct. There are three main trial management groups which may be involved in the set up and management of a clinical trial, depending on the trial size, design, number of sites and documented risk assessment of the ...
... Aim: To outline the various committees or groups involved in trial coordination and conduct. There are three main trial management groups which may be involved in the set up and management of a clinical trial, depending on the trial size, design, number of sites and documented risk assessment of the ...
Vertical saccades in senescence.
... samples/sec by a PDP 11/73 computer coil annulus (Skalar, The Netherlands). The amplitude of resolution in our system was 6 min of arc. Eye position signal was digitally differentiated to yield eye velocity using a 10-point moving window technique. For each eye movement with a velocity step greater ...
... samples/sec by a PDP 11/73 computer coil annulus (Skalar, The Netherlands). The amplitude of resolution in our system was 6 min of arc. Eye position signal was digitally differentiated to yield eye velocity using a 10-point moving window technique. For each eye movement with a velocity step greater ...
IRC MRI Safety Guidelines - UC Davis Imaging Research Center
... MRI researchers complete safety training prior to obtaining access to the MRI environment. It is expected that all MRI researchers should execute proper and orderly procedures every time studies and or developmental work is performed. UC Davis Imaging Research Center researchers and support staff as ...
... MRI researchers complete safety training prior to obtaining access to the MRI environment. It is expected that all MRI researchers should execute proper and orderly procedures every time studies and or developmental work is performed. UC Davis Imaging Research Center researchers and support staff as ...
Macular Carotenoids Conference
... Nature makes a great diversity of carotenoids; more than 700 different ones have been identified. In an ordinary diet, containing a good variety of fruit and vegetables, we probably ingest about 100, and 20-30 can usually be detected in the blood. And yet the macula specifically accumulates just two ...
... Nature makes a great diversity of carotenoids; more than 700 different ones have been identified. In an ordinary diet, containing a good variety of fruit and vegetables, we probably ingest about 100, and 20-30 can usually be detected in the blood. And yet the macula specifically accumulates just two ...